04:23 PM EDT, 05/05/2025 (MT Newswires) -- Neurocrine Biosciences ( NBIX ) reported Q1 non-GAAP earnings late Monday of $0.70 per diluted share, down from $1.20 a year earlier.

Analysts polled by FactSet expected $1.18.

Sales for the quarter ended March 31 were $572.6 million, up from $515.3 million a year earlier.

Analysts surveyed by FactSet expected $559.6 million.

The company reiterated its full year 2025 INGREZZA sales guidance of $2.50 billion to $2.60 billion.

Shares were up 14% in after-hours trading.